Tiancheng Pharmaceutical Holdings AG
Tiancheng Pharmaceutical Holdings AG: Start of mandatory additional acceptance period for Biotest tender offer
DGAP-News: Tiancheng Pharmaceutical Holdings AG / Key word(s): Offer PRESS RELEASE Start of mandatory additional acceptance period for Biotest tender offer As outlined in the offer document, the Bidder offers Biotest shareholders EUR28.50 per Biotest ordinary share and EUR19.00 per Biotest preference share in cash. The offer has been strongly and repeatedly recommended by the Biotest Management and Supervisory Board. Mr Wu Xu, CEO of Creat, said: “With more than 75% of Biotest ordinary shares having been tendered, we have reached an important milestone. We are encouraged by the large majority of Biotest ordinary shareholders who have already seized this unique opportunity and accepted our offer. To help secure Biotest’s long-term future, we invite all remaining ordinary and preference shareholders to accept the offer in the additional acceptance period in line with the Biotest Management and Supervisory Boards’ recommendation.” Shareholders who have not yet accepted the offer can still tender their shares to the Bidder at unchanged terms until the end of the additional acceptance period on 4 July 2017 at 24:00 hrs (Frankfurt am Main local time)/18:00 hrs (New York local time). The offer document as well as a presentation summarizing the key points of the offer are available at http://www.tiancheng-germany-pharmaceutical-angebot.de. The completion of the takeover offer remains subject to foreign investment control and merger control approvals. Merger control approval in the United States has already been granted. About Creat Group Corporation Important Notice Media Contact
21.06.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |